Japan OKs apixaban to prevent stroke, embolism with Afib

12/27/2012 | Pharmaceutical Business Review Online

Pfizer and Bristol-Myers Squibb obtained approval from Japanese regulators to market the anticoagulant apixaban for ischemic stroke and systemic embolism prevention in patients with nonvalvular atrial fibrillation. The approval was based on positive results of the late-stage ARISTOTLE trial. Apixaban has also been approved in Europe and Canada.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ